» Articles » PMID: 2865151

CNS-related (side-)effects of Beta-blockers with Special Reference to Mechanisms of Action

Overview
Specialty Pharmacology
Date 1985 Jan 1
PMID 2865151
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

beta-Adrenoreceptor antagonists are liable to produce behavioural side-effects such as drowsiness, fatigue, lethargy, sleep disorders, nightmares, depressive moods, and hallucinations. These undesirable actions indicate that beta-blockers affect not only peripheral autonomic activity but also some central nervous mechanisms. In experimental animals beta-blockers have been found to reduce spontaneous motor activity, to counteract isolation-, lesion-, stimulation- and amphetamine-induced hyperactivity, and to produce slow-wave and paradoxical sleep disturbances. Furthermore, central effects such as tranquilizing influences are used for the treatment of conditions such as anxiety. Several different mechanisms of action could be responsible for these CNS effects: Centrally mediated specific actions on centrally located beta-adrenergic receptors, known to exist downstream from, and at the terminals of, 'vigilance-enhancing' central noradrenergic pathways. Centrally mediated specific actions on centrally located receptors of the non-adrenergic type; an affinity of some beta-blockers towards 5-HT-receptors is well documented. Centrally mediated non-specific actions on centrally located neurones, owing to the membrane-stabilizing effects of beta-blockers. Peripherally mediated actions whereby beta-blockers induce changes in the autonomic activity in the periphery, which are relayed to the CNS to induce changes in activity of a variety of central systems. It can be assumed that with any one of the beta-blockers all these mechanisms come into play, yet with varying degrees depending on characteristics of the drugs such as lipophilicity and hydrophilicity, the ratio of antagonist versus (partial) agonist properties, affinity to 'alien' receptor sites, strength of membrane-stabilizing activity, stereospecific affinity, and potency.

Citing Articles

β-Blockers and risk of neuropsychiatric disorders: A systematic review and meta-analysis.

Eddin L, Preyra R, Ahmadi F, Jafari A, Omrani M, Muanda F Br J Clin Pharmacol. 2024; 91(2):325-337.

PMID: 39658346 PMC: 11773113. DOI: 10.1111/bcp.16361.


Pathophysiological mechanisms of post-myocardial infarction depression: a narrative review.

Garrels E, Kainth T, Silva B, Yadav G, Gill G, Salehi M Front Psychiatry. 2023; 14:1225794.

PMID: 37599890 PMC: 10436342. DOI: 10.3389/fpsyt.2023.1225794.


Metoprolol Inhibits Developmental Brain Sterol Biosynthesis in Mice.

Allen L, Mirnics K Biomolecules. 2022; 12(9).

PMID: 36139049 PMC: 9496459. DOI: 10.3390/biom12091211.


New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach.

Simonetta I, Riolo R, Todaro F, Tuttolomondo A Int J Mol Sci. 2022; 23(6).

PMID: 35328439 PMC: 8955051. DOI: 10.3390/ijms23063018.


Are Noradrenergic Transmission Reducing Drugs Antidepressants?.

Fitzgerald P Front Behav Neurosci. 2021; 15:673634.

PMID: 34658805 PMC: 8514666. DOI: 10.3389/fnbeh.2021.673634.


References
1.
Benkert O, Kohler B . Intrahypothalamic and intrastriatal dopamine and norepinephrine injections in relation to motor hyperactivity in rats. Psychopharmacologia. 1972; 24(2):318-25. DOI: 10.1007/BF00403650. View

2.
BRUNDIN J . Dual adreoceptor-mediated control of noradrenaline secretion from human vasoconstrictor nerves: facilitation by BETA-receptors and inhibitor by alpha-receptors. Acta Physiol Scand. 1975; 94(1):139-41. DOI: 10.1111/j.1748-1716.1975.tb05872.x. View

3.
Tyrer P . Use of beta-blocking drugs in psychiatry and neurology. Drugs. 1980; 20(4):300-8. DOI: 10.2165/00003495-198020040-00004. View

4.
GROSZ H . Effect of propranolol on active users of heroin. Lancet. 1973; 2(7829):612. DOI: 10.1016/s0140-6736(73)92433-1. View

5.
Greenblatt D, Shader R . On the psychopharmacology of beta adrenergic blockade. Curr Ther Res Clin Exp. 1972; 14(9):615-25. View